Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction

Cardiovascular Toxicology

Volumn 5, Issue 3, 2005, Pages 257-267

  Berthiaume, J M ^a,d   Oliveira, P J ^b   Fariss, M W ^c   Wallace, K B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COLORADO   (United States)

^d 262 Medical School   (United States)

Author keywords

tocopherol; Adriamycin; Cardiotoxicity; Doxorubicin; Mitochondria; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HEART PROTECTION; HISTOPATHOLOGY; MALE; MITOCHONDRIAL MEMBRANE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; CALCIUM; DIET; DOXORUBICIN; HEART DISEASES; INDICATORS AND REAGENTS; MITOCHONDRIA, HEART; MUSCLE PROTEINS; MYOCARDIUM; ORGAN SIZE; OXIDATIVE STRESS; OXYGEN CONSUMPTION; RATS; RATS, SPRAGUE-DAWLEY; VITAMIN E; VITAMINS;

ANIMALIA;

EID: 27144450968     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:5:3:257     Document Type: Article

References (43)

1. Iwasaki, T. and Suzuki, T. (1991). Ultrastructural alterations of the myocardium induced by doxorubicin. A scanning electron microscopic study. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 60(1):35-39.
2. Ferrans, V.J. (1978). Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat. Rep. 62(6):955-961.
3. Boucek, R.J. Jr., Olson, R. D., Brenner, D. E., Ogunbunmi, E. M., Inui, M., and Fleischer, S. (1987). The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J. Biol. Chem. 262(33):15,851-15,856.
4. Alexander, J., Dainiak, N., Berger, H.J., Goldman, L., Johnstone, D., Reduto, L., et al. (1979). Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N. Engl. J. Med. 300(6):278-283.
5. Wallace, K.B. (2003). Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol. Toxicol. 93(3):105-115.
6. Benchekroun, M.N., Catroux, P., Montaudon, D., and Robert, J. (1990). Development of mechanisms of protection against oxidative stress in doxorubicin-resistant rat tumoral cells in culture. Free Radic. Res. Commun. 11(1-3):137-144.
7. Lores Arnaiz, S. and Llesuy, S. (1993). Oxidative stress in mouse heart by antitumoral drugs: a comparative study of doxorubicin and mitoxantrone. Toxicology 77(1-2):31-38.
8. Sarvazyan, N. (1996). Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am. J. Physiol. 271(5 Pt 2):H2079-H2085.
9. Thayer, W.S. (1988). Evaluation of tissue indicators of oxidative stress in rats treated chronically with adriamycin. Biochem. Pharmacol. 37(11):2189-2194.
10. Olson, R.D., Boerth, R.C., Gerber, J.G., and Nies, A.S. (1981). Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci. 29(14):1393-1401.
11. Davies, K.J. and Doroshow, J.H. (1986). Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 261(7):3060-3067.
12. Doroshow, J.H. and Davies, K.J. (1986). Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. 261(7):3068-3074.
13. Mimnaugh, E.G., Trush, M.A., Bhatnagar, M., and Gram, T.E. (1985). Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem. Pharmacol. 34(6):847-856.
14. Mimnaugh, E.G., Trush, M.A., and Gram, T.E. (1981). Stimulation by adriamycin of rat heart and liver microsomal NADPH-dependent lipid peroxidation. Biochem. Pharmacol. 30(20):2797-2804.
15. Myers, C.E., McGuire, W.P., Liss, R.H., Ifrim, I., Grotzinger, K., and Young, R.C. (1977). Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197(4299):165-167.
16. Taatjes, D.J., Gaudiano, G., Resing, K., and Koch, T.H. (1997). Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem. 40(8):1276-1286.
17. Feinstein, E., Canaani, E., and Weiner, L.M. (1993). Dependence of nucleic acid degradation on in situ free-radical production by adriamycin. Biochemistry 32(48):13,156-13,161.
18. Sinha, B.K., Trush, M.A., Kennedy, K.A., and Mimnaugh, E.G. (1984). Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res. 44(7):2892-2896.
19. Serrano, J., Palmeira, C.M., Kuehl, D.W., and Wallace, K.B. (1999). Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim. Biophys. Acta 1411(1):201-205.
20. Palmeira, C.M., Serrano, J., Kuehl, D.W., and Wallace, K.B. (1997). Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim. Biophys. Acta 1321(2):101-106.
21. Sender, U., Bandow, J., Engelmann, S., Lindequist, U., and Hecker, M. (2004). Proteomic signatures for daunomycin and adriamycin in Bacillus subtilis. Pharmazie 59(1):65-70.
22. DeAtley, S.M., Aksenov, M.Y., Aksenova, M.V., Carney, J.M., and Butterfield, D.A. (1998). Adriamycin induces protein oxidation in erythrocyte membranes. Pharmacol. Toxicol. 83(2):62-68.
23. Smith, R.A., Kelso, G.F., Blaikie, F.H., Porteous, C.M., Ledgerwood, E.C., Hughes, G., et al. (2003). Using mitochondria-targeted molecules to study mitochondrial radical production and its consequences. Biochem. Soc. Trans. 31(Pt 6):1295-1299.
24. Dhanasekaran, A., Kotamraju, S., Kalivendi, S.V., Matsunaga, T., Shang, T., Keszler, A., et al. (2004). Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J. Biol. Chem. 279(36):37,575-37,587.
25. Zhao, K., Zhao, G. M., Wu, D., Soong, Y., Birk, A.V., Schiller, P.W., and Szeto H.H. (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem. 279(33):34,682-34,690.
26. Fariss, M.W., Chan, C.B., Patel, M., Van Houten, B., and Orenius, S., (2005). Role of mitochondria in toxic oxidative stress. Molecular Interventions 5:98-115.
27. Hovius, R., Lambrechts, H., Nicolay, K., and de Kruijff, B. (1990). Improved methods to isolate and subfractionate rat liver mitochondria. Lipid composition of the inner and outer membrane. Biochim. Biophys. Acta 1021(2):217-226.
28. Estabrook, R. (1967). Mitochondrial respiratory control and the polarographic measurement of ADP:O ratios. In: Methods in Enzymology, Vol. 10 (Estabrook RaP, M.E., ed.), Academic, New York: pp. 41-47.
29. Scarpa, A. (1979). Measurement of cation transport with metallochromic indicators. In: Methods in Enzymology, Vol. 56 (Fleischer IaP, L., ed.), Academic, New York: pp. 301-352.
30. Solem, L.E., Heller, L.J., and Wallace, K.B. (1996). Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. J. Mol. Cell Cardiol. 28(5):1023-1032
31. Levine, R.L., Williams, J.A., Stadtman, E.R., and Shacter, E. (1994). Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 233:346-357.
32. Tirmenstein, M.A., Watson, B.W., Haar, N.C., and Fariss, M.W. (1998). Sensitive method for measuring tissue alpha-tocopherol and alpha- tocopheryloxybutyric acid by high-performance liquid chromatography with fluorometric detection. J. Chromatogr. B. Biomed. Sci. Appl. 707(1-2):308-311.
33. Billingham, M.E., Mason, J.W., Bristow, M.R., and Daniels, J.R. (1978). Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 62(6):865-872.
34. Bristow, M.R., Minobe, W.A., Billingham, M.E., Marmor, J.B., Johnson, G.A., Ishimoto, B.M., et al. (1981). Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab. Invest. 45(2):157-168.
35. Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
36. Singal, P.K., Iliskovic, N., Li, T., and Kumar, D. (1997). Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11(12):931-936.
37. Singal, P.K., Li, T., Kumar, D., Danelisen, I., and Iliskovic, N. (2000). Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell Biochem. 207(1-2):77-86.
38. Santos, D.L., Moreno, A.J., Leino, R.L., Froberg, M.K., and Wallace, K.B. (2002). Carvedilolprotects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol. Appl. Pharmacol. 185(3):218-227.
39. Solem, L.E., Henry, T.R., and Wallace, K.B. (1994). Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 129(2):214-222.
40. Zhou, S., Starkov, A., Froberg, M.K., Leino, R.L., and Wallace, K.B. (2001). Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 61(2):771-777.
41. Oliveira, P.J., Bjork, J.A., Santos, M.S., Leino, R.L., Froberg, M.K., Moreno, A.J., and Wallace, K.B. (2004). Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol. Appl. Pharmacol. 200(2):159-168.
42. Exon, J.H., South, E.H., Taruscio, T.G., Clifton, G.D., and Fariss, M.W. (2004). Chemopreventive effect of dietary d-alpha-tocopheryl succinate supplementation on precancer colon aberrant crypt formation and vitamin E analogue levels in young and old rats. Nutr. Cancer 49(1):72-80.
43. Fariss, M.W. and Zhang, J.G. (2003). Vitamin E therapy in Parkinson's disease. Toxicology 189(1-2):129-146.